Voyager Therapeutics (VYGR) Non Operating Income (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Non Operating Income data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 36.72% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (down 41.7% YoY), and the FY2025 full-year result was $10.6 million, down 43.97% from the prior year.
• Non Operating Income climbed to $2.3 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $4.9 million in Q2 2024 to a low of $31000.0 in Q1 2022.
• A 5-year average of $2.8 million and a median of $3.2 million in 2023 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 5955.56% in 2022, while the deepest fall reached 99.21% in 2022.
• Tracing VYGR's Non Operating Income over 5 years: stood at $953000.0 in 2022, then surged by 230.95% to $3.2 million in 2023, then surged by 46.35% to $4.6 million in 2024, then sank by 54.27% to $2.1 million in 2025, then grew by 11.18% to $2.3 million in 2026.
• Business Quant data shows VYGR's Non Operating Income at $2.3 million in Q1 2026, $2.1 million in Q4 2025, and $2.8 million in Q3 2025.